Our Therapies

OXLUMO® Infusion Therapy

OXLUMO® (lumasiran) is a small interfering RNA (siRNA) therapeutic indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients. This medication targets the hydroxyacid oxidase 1 (HAO1) gene to reduce production of oxalate and is administered as a subcutaneous injection once monthly, with maintenance doses every 3 months.

Meet our Infusion Specialists

  • Natali Craig

    Natali Craig

    Product Designer

  • Phoenix Baker

    Phoenix Baker

    Engineering Manager

  • Candice Wu

    Candice Wu

    Backend Developer

  • Lana Steiner

    Lana Steiner

    Product Manager

For Provider

Simplify patient referrals and offer advanced treatment options with our infusion partnership program.

For Patient

There may be a better way to manage your condition – explore infusion therapy.

logo

Cutting-edge infusion therapies and injections for patients with complex chronic conditions and rare diseases.

instagramfacebooklinkedinTwitter

© 2024 violet health®: Infusion Care. All rights reserved.